Zydus, XOMA enter into licensing agreement for IL-2-Based Immuno-Oncology Therapy Medical Dialogues Bureau11 March 2020 3:30 AM GMTAhmedabad, Emeryville: Zydus Cadila and XOMA Corporation have announced they have entered into a licensing agreement to advance an IL-2-based immuno-on...
AstraZeneca fails to meet target endpoints in Phase II bladder cancer trial Medical Dialogues Bureau10 March 2020 4:00 AM GMTUSA: The Phase III DANUBE trial for Imfinzi (durvalumab) and Imfinzi plus tremelimumab in unresectable, Stage IV (metastatic) bladder cancer did not me...
